BACKGROUND: Streptococcus pneumoniae is a major cause of morbidity and mortality among adults 50 years of age and older in the United States. Pneumococcal conjugate vaccines are efficacious against pneumococcal disease in children and may also offer advantages in adults. METHODS: We performed a randomized, modified double-blind trial that compared a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in 831 pneumococcal vaccine naive adults 60-64 years of age. An additional group of 403 adults50-59 years of age receivedopen-label PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured at baseline, and at 1 month and 1 year after vaccination. RESULTS: In the randomized trial, the month 1 post-vaccination OPA geometric mean titers in the PCV13 group were statistically significantly higher than in the PPSV23 group for 8 of the 12 serotypes common to both vaccines and for serotype 6A, a serotype unique to PCV13, and were comparable for the other 4 common serotypes. The immune response to PCV13 was generally greater in adults50-59 years of age compared to adults 60-64 years of age. OPA titers declined from 1 month to 1 year after PCV13 administration but remained higher than pre-vaccination baseline titers. CONCLUSIONS:PCV13 induces a greater functional immune response than PPSV23 for the majority of serotypes covered by PCV13, suggesting that PCV13 could offer immunological advantages over PPSV23 for prevention of vaccine-type pneumococcal infection.
RCT Entities:
BACKGROUND:Streptococcus pneumoniae is a major cause of morbidity and mortality among adults 50 years of age and older in the United States. Pneumococcal conjugate vaccines are efficacious against pneumococcal disease in children and may also offer advantages in adults. METHODS: We performed a randomized, modified double-blind trial that compared a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in 831 pneumococcal vaccine naive adults 60-64 years of age. An additional group of 403 adults 50-59 years of age received open-label PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured at baseline, and at 1 month and 1 year after vaccination. RESULTS: In the randomized trial, the month 1 post-vaccination OPA geometric mean titers in the PCV13 group were statistically significantly higher than in the PPSV23 group for 8 of the 12 serotypes common to both vaccines and for serotype 6A, a serotype unique to PCV13, and were comparable for the other 4 common serotypes. The immune response to PCV13 was generally greater in adults 50-59 years of age compared to adults 60-64 years of age. OPA titers declined from 1 month to 1 year after PCV13 administration but remained higher than pre-vaccination baseline titers. CONCLUSIONS: PCV13 induces a greater functional immune response than PPSV23 for the majority of serotypes covered by PCV13, suggesting that PCV13 could offer immunological advantages over PPSV23 for prevention of vaccine-type pneumococcal infection.
Authors: G Fätkenheuer; A Kwetkat; M W Pletz; J Schelling; R-J Schulz; M van der Linden; T Welte Journal: Z Gerontol Geriatr Date: 2014-06 Impact factor: 1.281
Authors: Christine Juergens; Pierre J T de Villiers; Keymanthri Moodley; Deepthi Jayawardene; Kathrin U Jansen; Daniel A Scott; Emilio A Emini; William C Gruber; Beate Schmoele-Thoma Journal: Hum Vaccin Immunother Date: 2014-02-27 Impact factor: 3.452
Authors: Juan Carlos Tinoco; Christine Juergens; Guillermo M Ruiz Palacios; Jorge Vazquez-Narvaez; Hermann Leo Enkerlin-Pauwells; Vani Sundaraiyer; Sudam Pathirana; Elena Kalinina; William C Gruber; Daniel A Scott; Beate Schmoele-Thoma Journal: Clin Vaccine Immunol Date: 2014-12-10
Authors: D A van Kessel; T W Hoffman; H van Velzen-Blad; P Zanen; G T Rijkers; J C Grutters Journal: Clin Exp Immunol Date: 2014-07 Impact factor: 4.330